| 乌司他丁治疗新型冠状病毒肺炎可行性的研究进展 |
| |
| 引用本文： | 李彦静,孙美艳,李星月,王春玲,孙银贵,赵虹翔,赵晓勇.乌司他丁治疗新型冠状病毒肺炎可行性的研究进展[J].现代药物与临床,2022,45(1):186-192. |
| |
| 作者姓名： | 李彦静 孙美艳 李星月 王春玲 孙银贵 赵虹翔 赵晓勇 |
| |
| 作者单位： | 潍坊医学院附属医院 麻醉科, 山东 潍坊 261021;潍坊医学院麻醉学院 山东省医药卫生临床麻醉重点实验室, 山东 潍坊 261021;潍坊医学院附属医院 肝胆胰外科, 山东 潍坊 261021 |
| |
| 基金项目： | 山东省医药卫生科技发展计划项目（2019WS605，202104110334，202104110339，202104010549）；潍坊市科技发展计划项目（2021YX028）；潍坊医学院大学生创新创业培训项目（X2021523，X2021516）#共同 |
| |
| 摘 要： | 新型冠状病毒肺炎（COVID-19）仍在全球范围内传播，尚无特效药应用于临床。乌司他丁（ulinastatin）在抗炎方面发挥重要作用，临床上主要应用于急性胰腺炎、休克和弥散性血管内凝血等，其还具有抗氧化应激、抗凝、免疫调节作用，可能对于降低COVID-19的严重程度和死亡率有重要意义。主要结合乌司他丁的药理作用及其在治疗急性呼吸窘迫综合征、脓毒症肺损伤等COVID-19并发症中的临床应用，论述其应用于COVID-19的可行性，以期为该病的临床治疗及新药研发提供帮助。
|
| 关 键 词： | 乌司他丁 新型冠状病毒肺炎 急性呼吸窘迫综合征 脓毒症肺损伤 |
| 收稿时间： | 2021/9/1 0:00:00 |
Research progress of ulinastatin in treatment of COVID-19 |
| |
| LI Yanjing,SUN Meiyan,LI Xingyue,WANG Chunling,SUN Yingui,ZHAO Hongxiang,ZHAO Xiaoyong.Research progress of ulinastatin in treatment of COVID-19[J].Drugs & Clinic,2022,45(1):186-192. |
| |
| Authors: | LI Yanjing SUN Meiyan LI Xingyue WANG Chunling SUN Yingui ZHAO Hongxiang ZHAO Xiaoyong |
| |
| Institution: | Department of Anesthesiology, Affiliated Hospital of Weifang Medical College, Weifang 261021, China;Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, School of Anesthesiology, Weifang Medical University, Weifang 261021, China;Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Weifang Medical College, Weifang 261021, China |
| |
| Abstract: | Coronavirus disease 2019 (COVID-19) is still spreading worldwide. At present, no specific drug has been developed for the virus. Ulinastatin plays an important role in anti-inflammatory. Clinically, it is mainly used in acute pancreatitis, shock and disseminated intravascular coagulation. It also has the effects of antioxidant stress, anticoagulation and immune regulation, which may be of great significance to reduce the severity and mortality of COVID-19. Combined with the pharmacological effect of ulinastatin and its clinical application in the treatment of COVID-19 complications such as acute respiratory distress syndrome and sepsis lung injury, this paper discusses the feasibility of its application in COVID-19, so as to provide help for the clinical treatment and new drug research and development of this disease. |
| |
| Keywords: | ulinastatin coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome sepsis lung injury |
|
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
| 点击此处可从《现代药物与临床》下载免费的PDF全文 |
|
